Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Official title

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer：A Prospective, Open-label, Multi-center, Single-arm, Phase II Clinical Trial

Overview

This single-arm, prospective, multicenter, phase II study is designed to evaluate the efficacy and safety of ensartinib as neoadjuvant treatment in ALK positive, resectable for stage II to III non-small cell lung cancer patients.

Detailed description

This is a single-Arm, prospective, multicenter, phase II study, the primary endpoint is pathological complete response (pCR). Participants will receive ensartinib at 225 mg orally once a day taken with or without food for 12 weeks before surgical resection.

Interventions

• Drug Ensartinib
  Ensartinib 225 mg oral once daily 12 weeks

Primary outcome measures

• Pathological complete response (pCR) rate [Time frame: Within 2 month after surgery]

Secondary outcome measures (5)

• Major Pathological Response (MPR) rate [Time frame: Within 2 month after surgery]
• Objective Response Rate (ORR) [Time frame: Pre-operation]
• Incidence of Adverse Events [Time frame: Up to 1 month after surgery]
• Disease free survival (DFS) [Time frame: 3 years postoperatively]
• Overall Survival (OS) [Time frame: 5 years postoperatively]

Eligibility criteria

Inclusion criteria

• Give written informed consent before any study procedure.
• Male or female aged between 18 and 75 years old (including 18 and 75 years old).
• Histologically or cytologically documented lung adenocarcinoma within 60 days prior to study enrollment.
• Clinical stage II-III assessed by EBUS-TBNA or PET/CT can be resected.
• Patients confirmed as ALK fusion positive by RBK (NGS) test.
• Presence of at least one accurately measurable lesion, CT showing a maximum diameter of 10mm at baseline (except for lymph nodes with a short axis of 15mm required) and suitable for accurate repeat measurements.
• Eastern Cooperative Oncology Group (ECOG) performance status （PS） of 0 or 1.
• Adequate hematological, biochemical and organ functions, defined as follows

• Hemoglobin ≥90g/L. Note: transfusions are allowed to meet the required hemoglobin level;
• Absolute neutrophil count (ANC) ≥1.5× 10\^9/L
• Platelets ≥90 × 10\^9/L;
• Total bilirubin ≤ 2 times the upper limit of normal (ULN)；
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN;
• Creatinine ≤ 1.5× ULN and creatinine clearance ≥ 60 mL/min.
• Cardiopulmonary function suitable for surgical treatment (ECG, echocardiography, pulmonary function or blood gas analysis);
• At least 2 weeks prior to initial trial treatment female subjects should use adequate contraceptive measures, the pregnancy test must be negative and there is no ongoing breastfeeding. Otherwise, one of the following criteria must be met during screening to prove the possibility of no fertility:

• Postmenopausal is defined as amenorrhea for at least 12 months after stopping all exogenous hormone treatment over 50 years old;
• Women under the age of 50 should be regarded as menopause if they stop menopause for 12 months or more after stopping exogenous sex hormone therapy, and their LH and FSH levels are within the postmenopausal range of the institution;
• Irreversible surgical sterilization recorded by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but excluding tubal ligation.
• Men with partners of childbearing potential willing to use adequate contraceptive measures during the study and for 3 months after the last dose of study medication.

Exclusion criteria

• Mixed squamous cell carcinoma, large cell neuroendocrine carcinoma or small cell lung cancer;
• Prior treatment with any anti-cancer therapy;
• Pregnant female patients; breastfeeding female patients.
• Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior). All patients must try to avoid using or ingesting any drugs, herbal supplements and/or foods that are known to have induced effects on CYP3A4.
• Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) or known human immunodeficiency virus (HIV). Screening for chronic diseases is not a requirement.
• Past medical history of Interstitial lung disease（ILD）, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
• A history of hypersensitivity to active or inactive excipients of Ensartinib or to drugs of similar chemical structure or class to Ensartinib, and uncontrollable nausea and vomiting, chronic gastrointestinal disease, inability to swallow drugs, or had undergone major bowel resection that would interfere with adequate absorption of Ensartinib.
• Any of the following cardiac criteria:

• Mean resting corrected QT interval (QTc)>470 msec, obtained from 3 electrocardiograms (ECGs)
• Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third-degree heart block, second-degree heart block.
• Any factors that increase the risk of QTc prolongation or the risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
• A clear past history of neurological or psychiatric disorders, including epilepsy or dementia；
• Other circumstances deemed inappropriate by the investigator for participation in the trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06779539 · CLOG-0003

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗